Myriad Genetics Inc. (MYGN)

Trade MYGN now with
3/6/2018 7:06:32 AM Myriad Genetics Applauds AACU Position Statement On Molecular Testing For Risk Stratification In Prostate Cancer
3/1/2018 7:09:42 AM Myriad Genetics Demonstrates Strong Commitment To Preventing Hereditary Colon Cancer
2/7/2018 7:06:36 AM Myriad: MyRisk Hereditary Cancer Test Finds Over 12% Of Men With Prostate Cancer Carry An Inherited Genetic Mutation
2/6/2018 4:19:05 PM Myriad Genetics Inc. (MYGN) Has Raised Its FY18 EPS Estimate To 1.11 - 1.16 From 1.00 - 1.05
2/6/2018 4:18:26 PM Myriad Genetics Inc. (MYGN) Has Raised Its FY18 Revenue Estimate To $760 Mln - $770 Mln From $750 Mln - $770 Mln
2/6/2018 4:08:19 PM Myriad Genetics Q2 GAAP EPS Of $0.45 And Adjusted EPS $0.31
1/22/2018 7:08:34 AM Myriad Applauds Consensus Statement From Intl. Expert Panel On Screening Recommendations For Hereditary Prostate Cancer
1/3/2018 7:06:32 AM Myriad Genetics Reports Expanded Research Collaboration With AstraZeneca
12/12/2017 7:06:41 AM Myriad: BRACAnalysis CDx Test Effectively Identified Metastatic Breast Cancer Patients Who Responded To Talazoparib
11/10/2017 7:07:45 AM Myriad Collaborates With Dept Of VA In Trial Evaluating GeneSight Test To Improve Mental Health Outcomes For Veterans3
11/7/2017 4:07:00 PM Myriad Genetics Q1 GAAP EPS $1.15 And Adjusted EPS $0.26
11/6/2017 7:06:59 AM Myriad Genetics Partners With CareFirst BlueCross BlueShield On CED Study For Vectra DA Test